Read our Recent Headlines


Feb 27, 2015 by Dave Sobek

February 27 Biotech Update

The sector seems to be a little weaker than the market although the moves are relatively small, so there is probably not a lot one can read into it. That.

Share 0 Comments Read more
Feb 25, 2015 by Dave Sobek

February 25 Biotech Update

I am back but have not really followed the market the past couple of days. My sense is that it has been relatively weak and could be setting up for.

Feb 22, 2015 by Jason Chew

Pfenex: Biosimilar Enthusiasm Is High

San Diego’s Pfenex Inc. is riding the market’s enthusiasm for biosimilars, molecules that although not considered identical, can be automatically substituted for biologic drugs. Previously considered immune to generic competition,.

Feb 20, 2015 by Dave Sobek

February 20 Biotech Update

As much as I have disliked this recent move higher in terms of not trusting it, you have to respect how well the sector is climbing the wall of worry..

Feb 19, 2015 by Tony Pelz

Catalyst Watch – Vol. 3, Edition 3 (1/18/15)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Feb 18, 2015 by Dave Sobek

February 18 Biotech Update

I am back after a small break and I hope that nobody missed me. The market certainly did not miss me as not much has really happened on the news.

Feb 13, 2015 by Dave Sobek

February 13 Biotech Update

Market seems pretty benign but the sector appears a little heavy. As I have been saying the only thing we can have confidence in about the market is the lack.

More From All Reports

Introduction


Quick Facts

10

Analysts

500

Clients

22k

Followers

900

Reports

2.7k

Comments

5

Years

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!


      Join      

 Learn More